Wilson Sonsini Goodrich & Rosati represented Tempo Therapeutics in the transaction. Tempo Therapeutics, Inc. (“Tempo”) announced the completion of a $12 million Series A equity financing round, led by...
Tempo Therapeutics’ $12 Million Series A Financing Round
Halia Therapeutics’ $30 Milliion Series C Financing Round
Wilson Sonsini Goodrich & Rosati represented Halia Therapeutics in the transaction. Halia Therapeutics announced it raised $30 million in Series C financing round led by Todd Pedersen, with continued...
Oberland Capital’s $320 Million Investment in ImmunityBio
Wilson Sonsini Goodrich & Rosati represented ImmunityBio in the transaction. ImmunityBio, Inc., a clinical-stage immunotherapy company announced an up to $320 million royalty financing and equity...
Vivodyne’s $38 Million Seed Financing Round
Wilson Sonsini Goodrich & Rosati advised Khosla Ventures on the transaction. Vivodyne announced the close of $38 million in total seed financing, led by Khosla Ventures, with...
DermBiont’s $35.2 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati provided IP and corporate counsel to DermBiont in the transaction. DermBiont announced its $35.2 million Series B financing. The financing was led...
Iambic Therapeutics’ $100 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati advised Iambic on the transaction. Iambic Therapeutics announced the closing of an oversubscribed $100 million Series B financing. The round was co-led by...
Aspect Biosystems’ $2.7 Billion Collaboration with Novo Nordisk
Wilson Sonsini Goodrich & Rosati advised Aspect Biosystems on the transaction. Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics, and leading global...
Prometheus Biosciences’ $500 Million Shares Offering
Wilson Sonsini and Latham & Watkins advised Prometheus Biosciences on the deal, while Davis Polk & Wardwell advised the representatives of the several underwriters. Prometheus Biosciences,...
Harmonic Discovery’s $8 Million Seed Funding
Wilson Sonsini Goodrich & Rosati advised Harmonic Discovery on the deal. Harmonic Discovery, a therapeutics company building an integrated computational and experimental platform for kinase drug...
Belite Bio’s $36 Million IPO
Wilson Sonsini Goodrich & Rosati and O’Melveny advised Belite Bio on the deal. Belite Bio, Inc., a clinical-stage biopharmaceutical drug development company, announced the pricing of...
1859’s $40 Million Series A Funding Round
Wilson Sonsini Goodrich & Rosati advised 1859, Inc. on the deal. 1859, Inc., a platform company combining artificial intelligence and empirical pico-scale screening data at scale...
Arcaea’s $78 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Arcaea on the deal. Arcaea, a company launched on the Ginkgo Bioworks platform, announced its $78 million Series A to...